Use of GLP-1 drugs early in pregnancy should not cause alarm, analysis suggests

June 9, 2026 3:40 PM

Use of GLP-1 drugs early in pregnancy should not cause alarm, analysis suggests

Use of GLP-1 drugs for diabetes or obesity early in the first trimester of pregnancy, before a woman realizes she is pregnant, is not a cause for alarm, a large new data analysis suggests. These medications, which include Novo Nordisk’s semaglutide, sold as Ozempic and Wegovy, and Eli Lilly’s tirzepatide, sold as Zepbound and Mounjaro, are not recommended for use during pregnancy because their safety for the fetus is unknown and animal studies have suggested potential risks. Researchers at...

Procedure to treat type 2 diabetes helps keep off weight after patients stop GLP-1 drugs

April 24, 2026 4:38 PM

Procedure to treat type 2 diabetes helps keep off weight after patients stop GLP-1 drugs

An outpatient endoscopic procedure used to treat type 2 diabetes can help prevent people from regaining weight after they discontinue taking GLP-1 drugs, interim results from a clinical trial suggest. Patients in the trial had each lost at least 15% of their body weight, or about 40 pounds (18 kilograms) using Eli Lilly's tirzepatide before they stopped taking the drug, sold as Zepbound for obesity and Mounjaro for diabetes. Trial participants either underwent a procedure used to improve blood...